Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.
Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.
复制标题
唐氏综合征阿尔茨海默病血浆生物标志物的横断面探索：来自加强唐氏综合征研究纵向调查（LIFE-DSR）研究的早期数据。
DOI：
10.3390/jcm10091907
复制
发表时间：
2021-04-28
影响因子：
3.9
通讯作者：
Mobley W
中科院分区：
文献类型：
--
作者：
Hendrix JA;Airey DC;Britton A;Burke AD;Capone GT;Chavez R;Chen J;Chicoine B;Costa ACS;Dage JL;Doran E;Esbensen A;Evans CL;Faber KM;Foroud TM;Hart S;Haugen K;Head E;Hendrix S;Hillerstrom H;Kishnani PS;Krell K;Ledesma DL;Lai F;Lott I;Ochoa-Lubinoff C;Mason J;Nicodemus-Johnson J;Proctor NK;Pulsifer MB;Revta C;Rosas HD;Rosser TC;Santoro S;Schafer K;Scheidemantel T;Schmitt F;Skotko BG;Stasko MR;Talboy A;Torres A;Wilmes K;Woodward J;Zimmer JA;Feldman HH;Mobley W
随着医疗保健的改善，唐氏综合征（DS）人口正在迅速增长和老龄化。然而，随着寿命的延长，患阿尔茨海默病（AD）的风险也很高。LIFE-DSR研究（NCT 04149197）是一项纵向自然史研究，招募了270名25岁以上的DS成人。本研究旨在描述DS相关AD（DS-AD）的变化轨迹。目前的研究报告了对前90名入组受试者的横断面分析。血浆生物标志物磷酸化tau蛋白（p-tau）、神经丝轻链（NfL）、淀粉样β肽（Aβ1-40、Aβ1-42）和胶质细胞酸性蛋白（GFAP）采用先前发表的方法进行。基线访视的临床数据包括人口统计学以及严重损害成套测验（SIB）和唐氏综合征精神状态检查（DS-MSE）下的认知测量。生物标志物分布与受试者年龄的强统计学相关性。生物标志物数据有助于了解整个疾病谱的DS-AD。总的来说，生物标志物数据显示在大约40岁时开始的DS-AD进展的证据。在整个LIFE-DSR纵向研究人群中探索这些数据将是了解DS-AD病理生理学发作、进展和临床特征的重要资源。
With improved healthcare, the Down syndrome (DS) population is both growing and aging rapidly. However, with longevity comes a very high risk of Alzheimer’s disease (AD). The LIFE-DSR study (NCT04149197) is a longitudinal natural history study recruiting 270 adults with DS over the age of 25. The study is designed to characterize trajectories of change in DS-associated AD (DS-AD). The current study reports its cross-sectional analysis of the first 90 subjects enrolled. Plasma biomarkers phosphorylated tau protein (p-tau), neurofilament light chain (NfL), amyloid β peptides (Aβ1-40, Aβ1-42), and glial fibrillary acidic protein (GFAP) were undertaken with previously published methods. The clinical data from the baseline visit include demographics as well as the cognitive measures under the Severe Impairment Battery (SIB) and Down Syndrome Mental Status Examination (DS-MSE). Biomarker distributions are described with strong statistical associations observed with participant age. The biomarker data contributes to understanding DS-AD across the spectrum of disease. Collectively, the biomarker data show evidence of DS-AD progression beginning at approximately 40 years of age. Exploring these data across the full LIFE-DSR longitudinal study population will be an important resource in understanding the onset, progression, and clinical profiles of DS-AD pathophysiology.
登录
查看更多内容
影响因子：
4
作者：
Lott, Ira T.;Doran, Eric;Gillen, Daniel L.
通讯作者：
Gillen, Daniel L.
DOI：
10.1038/s41582-018-0132-6
发表时间：
2019-03
期刊：
Nature reviews. Neurology
影响因子：
--
作者：
Lott IT;Head E
通讯作者：
Head E
DOI：
10.1002/dad2.12057
发表时间：
2020-01-01
影响因子：
5.3
作者：
Henson, Rachel L.;Doran, Eric;Fagan, Anne M.
通讯作者：
Fagan, Anne M.
影响因子：
29
作者：
Hithersay, Rosalyn;Startin, Carla M.;Strydom, Andre
通讯作者：
Strydom, Andre
影响因子：
29
作者：
Janelidze S;Berron D;Smith R;Strandberg O;Proctor NK;Dage JL;Stomrud E;Palmqvist S;Mattsson-Carlgren N;Hansson O
通讯作者：
Hansson O